Five stable hybridomas have been obtained that secrete monoclonal antibodies against the D2-dopamine receptor-selective drug spiperone. Each monoclonal antibody has been characterized in terms of its ability to bind a range of dopamine-receptor-selective ligands. One monoclonal antibody has been purified by Protein A affinity chromatography and used to immunize mice. Anti-idiotypic antisera and one hybridoma secreting an anti-idiotypic monoclonal antibody were obtained and shown to inhibit [3H]spiperone binding to the anti-spiperone antibody used for immunization. Neither the antisera nor the anti-idiotypic monoclonal antibody, however, inhibited binding of [3H]spiperone to D2-dopamine receptors.
INTRODUCTION
Antibodies are useful tools in studying membranebound receptors, allowing valuable information to be obtained regarding their structure and function. Thus, for example, monoclonal antibodies have been generated against many parts of the nicotinic acetylcholine receptor and used as probes of its structure and function (Lindstrom, 1984) . In addition, Schoch et al. (1985) and Pfeiffer et al. (1984) have prepared monoclonal antibodies against the y-aminobutyrate/benzodiazepine and glycine receptors respectively as probes of the structures.
However, membrane-bound receptors generally exist at very low concentrations and purification procedures are frequently difficult. These problems have meant that the production of either polyclonal or monoclonal antibodies to receptors is rarely an easy task. As a result of these difficulties some workers have used an alternative route to obtain anti-receptor antibodies which bypasses the need to immunize animals with the purified receptor. This alternative method,-known as the 'anti-idiotypic approach' [reviewed in Haber (1983) , Strosberg et al. (1981) and Venter et al. (1984) ], is based on the hypothesis that, regardless of functional differences, macromolecules of the same specificity will show structural homologies in their binding sites. Thus, there may be similarities between the antigen-binding site of an antibody directed against a receptor-selective ligand and the ligand-binding site ofthe relevant receptor. Therefore, antibodies directed against the variable region of the anti-ligand antibody (anti-idiotypic antibodies) might also react with the receptor. Several groups have successfully used this approach to generate anti-receptor antibodies; for example, Schreiber et al. (1980 ), Homcy et al. (1982 and Guillet et al. (1984) have made antibodies to the ,?-adrenergic receptor, Ng & Isom (1984) and Glasel & Myers. (1985) have made antibodies to the opiate receptor and Cleveland et al. (1983) have made antibodies to the nicotinic acetylcholine receptor by this route.
We have been studying the D2-dopamine receptor for several years, using a variety of biochemical techniques (Strange, 1983a,b) . Antibodies directed against the receptor protein would help in further characterization of the receptor. Initial attempts to obtain such antibodies by immunization of animals with very impure receptor preparations were unsuccessful and therefore we decided to use the anti-idiotypic approach by initially making monoclonal antibodies to the dopamine antagonist spiperone and then anti-idiotypic antibodies to the anti-spiperone antibodies. We report here the successful production of both polyclonal and monoclonal antiidiotypic antibodies. These anti-idiotypic antibodies did not, however, recognize the D2-dopamine receptor.
MATERIALS AND METHODS Chemicals
Aminopterin, 8-azaguanine, 2,2'-azinobis-(3-ethylbenzthiazolinesulphonic acid), haemocyanin (from Limutus polyphemus), penicillin, streptomycin, Protein A-Sepharose, sheep anti-(mouse IgG)-peroxidase conjugate, thymidine and hypoxanthine were all from Sigma. The sheep anti-(mouse immunoglobulin) kit was from Serotec. All other chemicals were obtained as described in Hall et al. (1983) or Juszczak & Strange (1985) or were from commercial sources and were of the highest purity available. Cell lines and media NS-1 myeloma cells were kindly given by Dr. E. Billett (Department of Biochemistry, University ofNottingham, U.K.). The cells were maintained in RPMI 1640 medium supplemented with 10% foetal calf serum (both from Gibco). The growth medium contained additionally penicillin (50 units/ml), streptomycin (50 ,g/ml) and 8-azaguanine (0.1 mM). The cells were grown at 37°C in a humidified atmosphere containing 10% Co2. Juszczak & Strange (1985) . The number of spiperone molecules coupled per albumin molecule was determined from the absorption at 250 nm compared with control samples. Immunizations Balb/c mice (2-3 months old) received an intraperitoneal injection of 100 jug ofalbumin-spiperone [coupling ratio of spiperone: albumin 4:1 (mol/mol)] in Freund's complete adjuvant (Gibco), and 3 weeks later the mice received a booster intraperitoneal immunization of 100 ,ug of a second sample of albumin-spiperone (coupling ratio 16:1) in Freund's incomplete adjuvant (Gibco).
Anti-idiotypic antisera were produced by injecting the monoclonal antibody AS-I in several different forms (see Table 2 ). Four Balb/c mice (mice 1-4) were given an intraperitoneal injection of 50-100 ,g of the purified antibody emulsified in adjuvant as described previously. Alternatively, the purified AS-1 was first coupled to haemocyanin by using the procedure described by Reth et al. (1979) and then 10-20 ,ug of the conjugate was used to immunize the mice (mice 5 and 6) as described before. A further immunization procedure was to immunize mice (mice 7 and 8) with the hybridoma cells that secreted AS-I [fixed in 1 % (v/v) glutaraldehyde]. The hybridoma was shown to have the antibody in the membrane by a direct binding assay using [3H]spiperone (results not shown). The protocol for the latter immunization was the same as that described by Guillet et al. (1984) except that the mice were immunized intraperitoneally rather than intravenously.
Fusion of immune spleen cells with NS-1 cells
Fusions were performed essentially as described by Oi & Herzenberg (1980 (Oi & Herzenberg, 1980) . Monoclonal antibody was generated in culture supernatant by growing the cells beyond the point at which they begin to die. Antibody could be purified from the culture supernatant by using Protein A affinity chromatography as described in Oi & Herzenberg (1980) . Briefly, the antibody was taken up by the adsorbent at pH 8.6 and, following a thorough wash with buffer (sodium phosphate, 50 mm, pH 8.6), was eluted in 0.2 M-glycine/HCl, pH 2.8, and neutralized immediately with saturated Na2HPO4.
Radioimmunoassay
Culture supernatants were incubated with [3H]spiperone (1 nM approx.) in a final volume of 0.5 ml of buffer [sodium phosphate (10 mM), NaCl (154 mM), NaN3 (0.1 %) and gelatine (0.1 %) (pH 7.4)].
After 16 h at 4°C or 1 h at 25°C, when equilibrium was attained, free [3H]spiperone was removed with a charcoal/albumin mixture as described in Wheatley & Strange (1983) and bound radioactivity was determined by liquid-scintillation spectrometry. Putative anti-idiotypic samples (sera or culture supernatants) were assayed by their ability to inhibit [3H]spiperone binding in the radioimmunoassay after a preincubation with the monoclonal anti-spiperone antibodies (16 h, 4°C).
Isotypic determination
Isotypic determination of the monoclonal antibodies was performed by using an enzyme-linked immunosorbent assay. Sheep antisera directed against mouse immunoglobulin sub-classes were adsorbed onto poly-(vinyl chloride) microtitre plates (Flow Laboratories, Rickmansworth, Herts, U.K.) by incubating 100 gul (1: 500 dilution) for 16 h at 4°C in each well. The plates were washed three times by successively filling and emptying the wells with buffer [sodium phosphate (20 mM) and NaCl (150 mM) (pH 7.4) containing 0.05 0% Tween 20 (PBS/Tween)]. Remaining protein binding sites were blocked by incubating with 150,l of the PBS/Tween containing 0.1 % bovine serum albumin. After washing as before, 50 ,1 ofculture supernatant was added (6 h, 20°C) and then, after a further wash, bound mouse antibodies were detected by the addition of 50 ,u of a 1:500 dilution of a sheep anti-(mouse immunoglobulin)-peroxidase conjugate (16 h, 4°C). The plates were then washed three times with PBS/Tween and three times with PBS alone and the bound enzyme was detected by adding 100 l1 of the substrate 2,2'-azinobis-(3-ethylbenzthiazolinesulphonic acid) [1 mg/ml in buffer (0.1 M-citric acid/0.2 M-sodium phosphate, pH 4.0) containing H202 (0.05% )]. The reaction was terminated after 2 h at 20°C with 50 ,u of a solution of (0.05%) NaN3 in citric acid (0.1 M) and the A405 was determined in a Titertek Multiskan MC spectrophotometer (Flow Laboratories). D2-dopamine receptor binding assays
[3H]spiperone binding to caudate nucleus membranes was performed as described in Withy et al. (1980, 1981) to assay for D2-dopamine receptors. Sera and culture supematant [concentrated 6-fold by (NH4)2SO4 (50%) precipitation] were assayed for anti-(D2-dopamine receptor) antibodies by preincubating either 10 ,ul or 100 ,u1 respectively with the membranes (30 min, 25°C) before the addition of radioligand.
Soluble D2-dopamine receptors were obtained by solubilization of bovine caudate nucleus membranes with cholate as described in Hall et al. (1983) and assayed as in Wheatley & Strange (1983) . Sera were assayed for anti-receptor antibodies by preincubating 25,l with 425 ,ul of the soluble receptor preparation (16 h, 4°C) before adding the radioligand. Concentrated culture supernatant was assayed similarly for anti-receptor antibodies except that 225,c1 were preincubated with 225 ,ul of the soluble receptor preparation.
RESULTS

Production and characterization of monoclonal antibodies to spiperone
In order to obtain an immune response to spiperone the drug first had to be coupled to albumin. This was Table 2 . Titres of anti-idiotypic antera obtained from immunization of mice with monoclonal and-spiperone antibody AS-1 Titres were determined from full inhibition curves as in Fig. 1 with each serum being assayed in duplicate at the times shown (variation between determinations < 10%). The dilution of mouse serum that inhibited 50% of the maximum [IH]spiperone binding to AS-1 in the radioimmunoassay is given, for mice immunized with monoclonal antibody AS-1, the same antibody coupled to haemocyanin or the hybridoma secreting AS-1 fixed as described. aMaximum inhibition 10%; bno inhibition. K-light chain. AS-I was ofthe }2b subclass, whereas AS-2, AS-3, AS-4 and AS-S were all of the yi sub-class.
Production and characterization of anti-idiotypic antibodies
As AS-I was of the Y2b sub-class it could be easily purified from other proteins in the culture supernatant by using Protein A affinity chromatography (Goding, 1978 case, in addition to the booster immunization in Freund's incomplete adjuvant the mouse also received intraperitoneal immunisations 2 days and 1 day before the fusion without adjuvant according to the method of Stahli et al. (1980) . This mouse (mouse 6) had the highest titre of anti-idiotypic antibody in its -serum and one culture supernatant was detected as positive in the anti-idiotypic assay from approx. 300 wells that contained growing hybridomas. The cells from the positive well were grown and cloned to yield a stable monoclonal hybridoma cell line secreting the antibody designated AID-1. The anti-idiotypic effect of AID-1 in culture supernatant is shown in Fig. 2 . It was of the Y2b sub-class with a K-light chain.
The anti-idiotypic antiserum from mouse 6 and the monoclonal antibody AID-1 could not inhibit [3H]spiperone binding to any of the other four monoclonal anti-spiperone antibodies or a monoclonal anti-haloperidol antibody (Table 3) developed by R. Juszczak & P. G. Strange (unpublished work) . Thus the idiotypic determinant recognised on AS-1 is 'private', i.e. it does not occur on other monoclonal antibodies to spiperone or haloperidol.
Anti-D2-dopamine receptor activity of anti-idiotypes
The antiserum from mice 1-4 and the culture supernatant containing AID-1 [concentrated 6-fold by (NH4)2SO precipitation] were assayed for the presence of anti-D2-dopamine receptor activity by their ability to inhibit [3H]spiperone binding to soluble receptors (Table   4 ). In addition the serum from mice 5 and 6 and the concentrated culture supernatant were assayed for their effects on [3H]spiperone binding to membrane bound receptors (Table 4) . However, in none of these cases did the anti-idiotypes show any significant inhibition. Thus although both polyclonal and monoclonal anti-idiotypic antibodies were produced to the monoclonal antispiperone antibodies they did not recognise the D2-dopamine receptor.
DISCUSSION
The anti-idiotypic approach to producing anti-receptor antibodies is essentially a two-step process. Firstly antibodies are produced to a receptor-selective ligand with the aim of producing an antigen binding site that resembles the binding site of the receptor for the ligand. Thus the anti-ligand antibody can be considered equivalent to the receptor. The second step is to produce antibodies to the idiotype of the anti-ligand antibodies. If the anti-ligand antibody has a similar specificity to the receptor the anti-idiotypic antibodies may cross-react with the receptor. Thus anti-receptor antibodies can in principle be made without needing to immunize animals with the purified receptor.
In this study five monoclonal antibodies were made to the D2-dopamine receptor antagonist spiperone. In some respects the binding specificity of these monoclonal antibodies was similar to that of the D2-dopamine receptor in that the antibodies would bind spiperone with a high affinity and would also recognize the dopamine antagonists domperidone and haloperidol. However, in other ways they were markedly different as they showed no discrimination between the stereoisomers of butaclamol and sulpiride and also could not interact with the agonist apomorphine. It is possibly better to regard the monoclonal antibodies to spiperone as recognizing structures related to spiperone whilst showing low affinity for unrelated structures.
The monoclonal antibody AS-I was used to produce an anti-idiotypic response because it could be easily purified from culture supernatants by using a Protein A adsorbent. The highest titre anti-idiotypic responses were obtained when the purified AS-I was coupled to haemocyanin before immunization, a result which is in agreement with Reth et al. (1979) and Phillips et al. (1984) . No anti-idiotypic response was detected when the idiotype-bearing hybridoma was used to immunize the mice, a result which is in contrast with the report of Guillet et al. (1984) . One hybridoma was made that secreted anti-idiotypic antibody by using the spleen of a mouse that was immunized with the antibody-haemocyanin conjugate. However neither the antisera from mice 1-6 or antibody AID-1 showed any ability to recognize either membrane-bound or soluble D2-dopamine receptors. The most probable reason for this result was that the anti-spiperone antibodies did not resemble the D2-dopamine receptor sufficiently. It is important to mention that, even after coupling to albumin, spiperone retained its ability to bind to the D2-dopamine receptor although the affinity was reduced. Thus the receptoractive part of spiperone would have been available to stimulate an immune response although it seems that the anti-spiperone antibodies generated did not recognize exactly that part of the molecule.
Several groups have successfully used the anti-idiotypic approach to generate anti-receptor antibodies (Schreiber et al., 1980; Rockson et al., 1980; Homcy et al., 1982; Guillet et al., 1984; Ng & Isom, 1984; Wasserman et al., 1982; Glasel & Myers, 1985) . The anti-ligand antibodies in these studies are often more similar to the particular receptor than is the case in the present study. Thus, for Vol. 238 example, Rockson et al. (1980) made an antiserum to the ,l-adrenergic antagonist alprenolol and purified a fraction of the antibodies that would recognize both agonists and antagonists and also showed some stereospecificity in the recognition of the stereoisomers of propranolol. Similarly, the antiserum made by Ng & Isom (1984) Guillet et al. (1984) [described in Chamat et al. (1984) ] showed only very low stereospecificity and had an affinity for agonists much lower than that for antagonists, in contrast to the ,-adrenergic receptor identified by Lefkowitz & Williams (1977) . Therefore, even when the anti-ligand antibody does not closely resemble the receptor, the approach has been used successfully.
Anti-idiotypic antibodies have also been described from an alternative view as containing an 'internal image' of the ligand at their binding site (Jerne, 1974; Nisonoff & Lamoyi, 1981) . Thus the anti-idotypic antibody is viewed as having a structure within its binding site that is similar to the ligand and therefore it can essentially behave in a similar manner to the ligand. However this does not seem to be the case in this study, as the anti-idiotypic antibodies would not recognize several proteins that bind spiperone and related substances with a high affinity. Thus, although they recognised AS-1, they could not bind other monoclonal antibodies to spiperone or a monoclonal antibody to haloperidol. In addition they did not recognise the D2-dopamine, 5HT2-serotonin or az-adrenergic receptors (the present paper; W. M. Abbott & P. G. Strange, unpublished work) all of which are known to have a high affinity for spiperone (Leysen et al., 1981) .
There has been a recent report of the production of antibodies to spiperone and their anti-idiotypes which in preliminary results seemed to cross-react with the D2-dopamine receptor (Schreiber et al., 1983) . However, as the only definition of anti-receptor activity was the ability to bind homogenates of rat and calf striatum (an area rich in D2-dopamine receptors) but not muscle or cerebellum (areas with few or no D2-dopamine receptors) the results remain only tentative at present. In conclusion we were unsuccessful in using the anti-idiotypic approach for raising anti-(D2 dopamine receptor) antibodies in this study. The most probable reason was that the monoclonal antibodies generated to spiperone did not sufficiently resemble the D2-dopamine receptor and thus subsequent anti-idiotypes would not cross-react with the receptor. If the approach is to be applied successfully then the anti-ligand antibody would probably need to have a closer resemblance to the D2-dopamine receptor than those made in this study. With this in mind it would be of interest to produce antibodies to more selective D2-dopamine receptor ligands such as sulpiride or domperidone, or alternatively to dopamine agonists. Juszczak & Strange (1985) have raised polyclonal antibodies against haloperidol which showed a somewhat greater resemblance to the D2 receptor than the antibodies generated in the present paper. Anti-idiotypic antibodies that cross-reacted with D,-dopamine receptors were obtained in one study using these anti-haloperidol antibodies, indicating that this general approach may still be useful.
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